Literatura académica sobre el tema "Dopamine type I receptor"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Dopamine type I receptor".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Dopamine type I receptor"
Shariati, G. H., G. Ahangari, M. R. Asadi, F. Poyafard y H. R. Ahmadkhaniha. "Dopamine Receptor Gene Expression Changes in Peripheral Blood Mononuclear Cells from Schizophrenic Patients Treated with Haloperidol and Olanzapine". European Journal of Inflammation 7, n.º 2 (mayo de 2009): 71–76. http://dx.doi.org/10.1177/1721727x0900700203.
Texto completoSarkar, D. K., K. Chaturvedi, S. Oomizu, N. I. Boyadjieva y C. P. Chen. "Dopamine, Dopamine D2 Receptor Short Isoform, Transforming Growth Factor (TGF)-β1, and TGF-β Type II Receptor Interact to Inhibit the Growth of Pituitary Lactotropes". Endocrinology 146, n.º 10 (1 de octubre de 2005): 4179–88. http://dx.doi.org/10.1210/en.2005-0430.
Texto completoPeiser, Christian, Marcello Trevisani, David A. Groneberg, Q. Thai Dinh, Doerthe Lencer, Silvia Amadesi, Barbara Maggiore, Selena Harrison, Pierangelo Geppetti y Axel Fischer. "Dopamine type 2 receptor expression and function in rodent sensory neurons projecting to the airways". American Journal of Physiology-Lung Cellular and Molecular Physiology 289, n.º 1 (julio de 2005): L153—L158. http://dx.doi.org/10.1152/ajplung.00222.2004.
Texto completoMyslivecek, Jaromir. "Dopamine and Dopamine-Related Ligands Can Bind Not Only to Dopamine Receptors". Life 12, n.º 5 (19 de abril de 2022): 606. http://dx.doi.org/10.3390/life12050606.
Texto completoHelms, My N., Xi-Juan Chen, Semra Ramosevac, Douglas C. Eaton y Lucky Jain. "Dopamine regulation of amiloride-sensitive sodium channels in lung cells". American Journal of Physiology-Lung Cellular and Molecular Physiology 290, n.º 4 (abril de 2006): L710—L722. http://dx.doi.org/10.1152/ajplung.00486.2004.
Texto completoDing, Guoliang, Rob F. Wiegerinck, Ming Shen, Anca Cojoc, Carlo M. Zeidenweber y Mary B. Wagner. "Dopamine increases L-type calcium current more in newborn than adult rabbit cardiomyocytes via D1 and β2 receptors". American Journal of Physiology-Heart and Circulatory Physiology 294, n.º 5 (mayo de 2008): H2327—H2335. http://dx.doi.org/10.1152/ajpheart.00993.2007.
Texto completoMORA-FERRER, CARLOS y VOLKER GANGLUFF. "D2-dopamine receptor blockade impairs motion detection in goldfish". Visual Neuroscience 17, n.º 2 (marzo de 2000): 177–86. http://dx.doi.org/10.1017/s0952523800171196.
Texto completoHayashida, Yuki y Andrew T. Ishida. "Dopamine Receptor Activation Can Reduce Voltage-Gated Na+ Current by Modulating Both Entry Into and Recovery From Inactivation". Journal of Neurophysiology 92, n.º 5 (noviembre de 2004): 3134–41. http://dx.doi.org/10.1152/jn.00526.2004.
Texto completoPfeiffer-Linn, C. y E. M. Lasater. "Dopamine modulates in a differential fashion T- and L-type calcium currents in bass retinal horizontal cells." Journal of General Physiology 102, n.º 2 (1 de agosto de 1993): 277–94. http://dx.doi.org/10.1085/jgp.102.2.277.
Texto completoMilienne-Petiot, Morgane, Lucianne Groenink, Arpi Minassian y Jared W. Young. "Blockade of dopamine D1-family receptors attenuates the mania-like hyperactive, risk-preferring, and high motivation behavioral profile of mice with low dopamine transporter levels". Journal of Psychopharmacology 31, n.º 10 (27 de septiembre de 2017): 1334–46. http://dx.doi.org/10.1177/0269881117731162.
Texto completoTesis sobre el tema "Dopamine type I receptor"
Hatcher-Solis, Candice N. "PHARMACOLOGICAL IMPLICATIONS OF ADENOSINE 2A RECEPTOR- DOPAMINE TYPE 2 RECEPTOR HETEROMERIZATION". VCU Scholars Compass, 2016. http://scholarscompass.vcu.edu/etd/4458.
Texto completoZANINOVICH, OREL ANTHONY. "THE CLONING OF AN INDR-TYPE DOPAMINE RECEPTOR IN MANDUCA SEXTA". Thesis, The University of Arizona, 2008. http://hdl.handle.net/10150/192256.
Texto completoMann, Miranda Jane. "A neuropsychological investigation of dopamine receptor 4 differences among attention deficit hyperactivity disorder-combined type and control children /". Digital version accessible at:, 2000. http://wwwlib.umi.com/cr/utexas/main.
Texto completoGorji, Hassan. "Role of adenylyl cyclase type 5 in the regulation of the dopamine D3 receptor phosphorylation". Thesis, University of Ottawa (Canada), 2006. http://hdl.handle.net/10393/27364.
Texto completoMaier, Annette Louise. "Comparative regional ontogeny of dopamine D₁ receptor binding and mRNA expression in pre- and postnatal rat brain /". Zürich, 1994. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=10902.
Texto completoEtchepare, Laetitia. "Role of glutamate N-Methyl-D-Aspartate receptor surface trafficking in the firing pattern of midbrain dopaminergic neurons". Thesis, Bordeaux, 2017. http://www.theses.fr/2017BORD0849/document.
Texto completoMidbrain dopaminergic (DA) neurons play several key functions in the brain such as the processing of salient information but are also associated with the emergence of pathologies including Parkinson’s disease and drug addiction. Because these processes have in common to modify the firing activity of midbrain DA neurons, it is of crucial importance to understand the mechanisms underlying this activity. Among the various ions channels and receptors involved in the generation of the firing activity of midbrain DA neurons, glutamate N-methyl-D-aspartate receptors (NMDAR) and calciumdependent potassium SK channels strongly modulate the firing pattern and functionally interact in several neuronal types including DA neurons. However, the mechanisms by which they regulate the firing pattern are poorly understood. Since the functional coupling between NMDAR and SK channels depends on their relative membrane distribution, we hypothesized that the lateral diffusion of NMDAR, which regulates the surface localization of the receptor, could play a role in the firing pattern of midbrain DA neurons through the modulation of SK channel function. We showed first that membrane NMDAR was highly mobile in cultured DA neurons. Alteration of its surface trafficking by a crosslink with NMDAR antibodies profoundly modified the regularity of the firing pattern of DA neurons in midbrain slices, whereas pharmacological blockade of NMDAR did not affect it. Furthermore, a SK channel blocker, which induces a similar change in the firing regularity in control conditions, was less effective when NMDAR surface trafficking was altered. Taken together, these results demonstrate that NMDAR surface dynamics modulate the firing pattern of midbrain DA neurons by regulating SK channel function
Roberts-Crowley, Mandy L. "Modulation of Cav1.3 L-Type Calcium Channels by Arachidonic Acid and Muscarinic M1 Receptors: A Dissertation". eScholarship@UMMS, 2007. https://escholarship.umassmed.edu/gsbs_diss/348.
Texto completoLucas, Guillaume. "Etude in vivo des modalités d'intervention de la sérotonine et des récepteurs sérotoninergiques de type 5-HT/2A/2C, 5-HT3 et 5-HT4 dans le contrôle de la transmission dopaminergique nigro-striée et mésoaccumbale chez le rat". Bordeaux 2, 1999. http://www.theses.fr/1999BOR28692.
Texto completoHegron, Alan. "Implication des récepteurs de la mélatonine dans les troubles neurologiques et le diabète de type 2 et identification de régions clés du récepteur MT1 responsables de sa sélectivité fonctionnelle". Thesis, Université Paris-Saclay (ComUE), 2018. http://www.theses.fr/2018SACLS555/document.
Texto completoMelatonin is a neurohormone mainly released from the pineal gland in a circadian manner acting through two G protein-coupled receptors (GPCRs) called MT1 and MT2. Melatonin regulates many important physiological functions. Regulation of dopamine (DA) and glucose levels are two of them but how they do this is not clear.Extracellular DA levels are mainly regulated by its transporter (DAT) which mediates DA re-uptake into presynaptic nerve termini to prevent DA receptor hyperactivation in the presynaptic cleft. Consequently, we verified the role of DAT in the regulation of the DA system by melatonin. We showed that MT1 and MT2, by interacting with the immature non-glycosylated form of DAT retain DAT in the endoplasmic reticulum thus regulating DAT cell surface expression and DA reuptake. Consistently, mice with targeted deletion of MT1 and MT2 show markedly enhanced DA uptake in striatal synaptosomes and decreased amphetamine-induced locomotor activity. Collectively, we revealed here a molecular link between the melatonin and DA systems, which is based on the formation of a molecular complex between melatonin receptors and DAT.To better understand the role of melatonin on the regulation of glucose levels, we studied the involvement of genetic variants of MT2 in the development of type 2 diabetes (T2D). Previous studies showed that natural loss-of-function variants of MT2 associate with T2D risk. To determine more precisely the defective properties linked to T2D risk we monitored spontaneous and melatonin-induced activation of different signaling pathways by 40 MT2 variants. We show that defects in melatonin-induced Gαi and Gαz activation and spontaneous βarrestin-2 recruitment are most significantly associated to T2D risk. Experimental results correlated well with those predicted by evolutionary lineage analysis. This work will help to propose personalized treatments for MT2 variant carriers to recover their defective responses.Sequencing of 9393 individuals resulted in the identification of 32 natural MT1 variants. MT1 wild-type and variants were functionally characterized in bioluminescence resonance energy transfer (BRET) assays. We showed that MT1 activates Gαi/o, Gα12 and Gα15 proteins and recruits βarrestin-2. Analyzes of results by non-linear matrix factorization revealed the existence of 5 clusters characterized by different signaling profiles. Computational homology modeling of the 3D model of MT1 helped to determine the impact of each variant on receptor activation and interaction with G proteins and βarrestin-2. Collectively, our data illustrate that natural variants are powerful tools to understand the molecular basis of GPCR function. Overall, this work contributes to our understanding of the function of melatonin receptors and highlights their importance in the regulation of the DA system and glucose homeostasis. Our results will open new, personalized therapeutic options for patient suffering from a defective DA system or T2D
Thirtamara, Rajamani Keerthi Krishnan. "Animal Models of Drug Addiction and Autism Spectrum Disorders". The Ohio State University, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=osu1386011455.
Texto completoLibros sobre el tema "Dopamine type I receptor"
Tupala, Erkki. Dopamine receptors and transporters in type 1 and 2 alcoholism measured with postmortem human whole hemisphere autoradiography. Kuopio: University of Kuopio, 2001.
Buscar texto completoTiberi, Mario. Dopamine receptor technologies. New York, NY: Humana Press, 2015.
Buscar texto completoTiberi, Mario, ed. Dopamine Receptor Technologies. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2196-6.
Texto completoDonthamsetti, Prashant Chandra. Dissecting Dopamine D2 Receptor Signaling. [New York, N.Y.?]: [publisher not identified], 2015.
Buscar texto completoL, Waddington John, ed. D1:D2 dopamine receptor interactions. London: Academic Press, 1993.
Buscar texto completoBoileau, Isabelle y Ginetta Collo, eds. Therapeutic Applications of Dopamine D3 Receptor Function. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23058-5.
Texto completoKnapp, Mark. Development of dopamine receptor expressing adenoviral vectors. Ottawa: National Library of Canada, 1997.
Buscar texto completoR, Demirdamar y Jenner Peter 1946-, eds. Dopamine receptor subtypes: From basic science to clinical application. Amsterdam: IOS Press, 1998.
Buscar texto completoRay, Avi Andrew. SH3 binding domains in the dopamine D(3) receptor. Ottawa: National Library of Canada, 1999.
Buscar texto completoZawarynski, Paul. Dopamine D2 receptor monomers, dimers and higher order oligomers. Ottawa: National Library of Canada, 1998.
Buscar texto completoCapítulos de libros sobre el tema "Dopamine type I receptor"
Turco, Raymond. "Dopamine Receptor". En Encyclopedia of Animal Cognition and Behavior, 1–5. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-47829-6_1256-1.
Texto completoTurco, Raymond. "Dopamine Receptor". En Encyclopedia of Animal Cognition and Behavior, 2120–25. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-319-55065-7_1256.
Texto completoFuxe, Kjell, Daniel Marcellino, Diego Guidolin, Amina Woods y Luigi Agnati. "Dopamine Receptor Oligomerization". En The Dopamine Receptors, 255–80. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_10.
Texto completoHazelwood, Lisa A., R. Benjamin Free y David R. Sibley. "Dopamine Receptor-Interacting Proteins". En The Dopamine Receptors, 219–54. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_9.
Texto completoDeth, Richard C. "The Dopamine D4 Receptor". En Molecular Origins of Human Attention, 23–36. Boston, MA: Springer US, 2003. http://dx.doi.org/10.1007/978-1-4615-0335-4_4.
Texto completoRichtand, Neil M., Laurel M. Pritchard y Lique M. Coolen. "Dopamine Receptor Alternative Splicing". En Dopamine and Glutamate in Psychiatric Disorders, 45–61. Totowa, NJ: Humana Press, 2005. http://dx.doi.org/10.1007/978-1-59259-852-6_2.
Texto completoCivelli, Olivier, James Bunzow, Paul Albert, Hubert H. M. Van Tol y David Grandy. "The Dopamine D2 Receptor". En Molecular Biology of G-Protein-Coupled Receptors, 160–69. Boston, MA: Birkhäuser Boston, 1992. http://dx.doi.org/10.1007/978-1-4684-6772-7_7.
Texto completoCepeda, Carlos, Véronique M. André, Emily L. Jocoy y Michael S. Levine. "Dopamine Receptor Modulation of Glutamatergic Neurotransmission". En The Dopamine Receptors, 281–302. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_11.
Texto completoLee, Frankie H. F. y Albert H. C. Wong. "Dopamine Receptor Genetics in Neuropsychiatric Disorders". En The Dopamine Receptors, 585–632. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_19.
Texto completoMoreira, Irina S., Lei Shi, Zachary Freyberg, Spencer S. Ericksen, Harel Weinstein y Jonathan A. Javitch. "Structural Basis of Dopamine Receptor Activation". En The Dopamine Receptors, 47–73. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_3.
Texto completoActas de conferencias sobre el tema "Dopamine type I receptor"
Kamasak, Mustafa E., Charles A. Bouman, Bradley T. Christian y Evan D. Morris. "Imaging D2-Dopamine Receptor using PET". En 2007 IEEE 15th Signal Processing and Communications Applications. IEEE, 2007. http://dx.doi.org/10.1109/siu.2007.4298698.
Texto completoMoritz, Amy E., Nora S. Madaras, Kirsten K. Snyder, Noelia M. Boldizsar, Raphael Haider, Julia Drube, Arun K. Ghosh, John JG Tesmer, Carsten Hoffmann y David R. Sibley. "Regulation of Dopamine Receptor Subtypes by G Protein-Coupled Receptor Kinase Isoforms". En ASPET 2024 Annual Meeting Abstract. American Society for Pharmacology and Experimental Therapeutics, 2024. http://dx.doi.org/10.1124/jpet.159.988010.
Texto completoLiu, X., J. Guan, F. Tao y B. Mao. "Acupuncture Zusanli Regulate COPD Inflammation Through Dopamine D2 Receptor". En American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4755.
Texto completoHarrison, J. M., I. Nir, M. Rubinstein, M. J. Low, D. K. Grandy y P. M. Iuvone. "Retinal Function in Dopamine D4 Receptor Knockout (D4KO) Mice". En Vision Science and its Applications. Washington, D.C.: OSA, 2000. http://dx.doi.org/10.1364/vsia.2000.fd2.
Texto completoJavadi, Arman, Nicholas Forsythe, Alaa Refaat, Jessica-Ann Weir, Hajrah Khawaja, David Waugh, Rohinton Tarapore, Joshua E. Allen, Patrick Johnston y Sandra Van Schaeybroeck. "Abstract 3448: Targeting the dopamine receptor 2 inBRAFmutant colorectal cancer". En Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-3448.
Texto completoUysal, Mehmet Atilla, Ulgen Sever y Sacide Pehlivan. "The dopamine receptor D4 VNTR 48bp gene variant in nicotine addiction". En ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.oa1486.
Texto completoRaghuraman, Gayatri, Nanduri R. Prabhakar y Ganesh K. Kumar. "Dopamine D1 Receptor Signaling Mediates Altered GABA Synthesis By Intermittent Hypoxia". En American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a6630.
Texto completoBlake, Keyana, Basant Hens y Anthony J. Baucum. "Investigating the role of spinophilin in mediating Dopamine D2 Receptor Activity". En ASPET 2024 Annual Meeting Abstract. American Society for Pharmacology and Experimental Therapeutics, 2024. http://dx.doi.org/10.1124/jpet.321.940880.
Texto completoWen, Ruojian, Xiaoqing Chen, Dan Huang, Minjie Chen y Yuwei Liu. "Sleep Deprivation Increased Dopamine D2 Receptor Expression through Downregulation of miR-9". En 2015 7th International Conference on Information Technology in Medicine and Education (ITME). IEEE, 2015. http://dx.doi.org/10.1109/itme.2015.122.
Texto completoMadaras, Nora S., Michele L. Rankin, R. Benjamin Free, Raphael Haider, Julia Drube, Arun K. Ghosh, John JG Tesmer, Carsten Hoffmann, David R. Sibley y Amy E. Moritz. "Delineation of the G Protein-Coupled Receptor Kinase Phosphorylation Sites Within the D1 Dopamine Receptor and Their Role in Regulating Receptor Function". En ASPET 2023 Annual Meeting Abstracts. American Society for Pharmacology and Experimental Therapeutics, 2023. http://dx.doi.org/10.1124/jpet.122.154110.
Texto completoInformes sobre el tema "Dopamine type I receptor"
Dr. Jogeshwar Mukherjee. Development of dopamine receptor radiopharmaceuticals for the study of neurological and psychiatric disorders. Office of Scientific and Technical Information (OSTI), enero de 2009. http://dx.doi.org/10.2172/944919.
Texto completoMukherjee, J. Development of dopamine receptor radiopharmaceuticals for the study of neurological and psychiatric disorders. Progress report 1994--1997. Office of Scientific and Technical Information (OSTI), agosto de 1999. http://dx.doi.org/10.2172/764610.
Texto completoReiss, Michael. Type I Receptor Kinase Inhibitors - A Novel Treatment for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, junio de 2002. http://dx.doi.org/10.21236/ada408030.
Texto completoFagan, Dedra. Type-I Insulin-Like Growth Factor Receptor (IGF1R)-Estrogen Receptor (ER) Crosstalk Contributes to Antiestrogen Therapy Resistance in Breast Cancer Cells. Fort Belvoir, VA: Defense Technical Information Center, febrero de 2013. http://dx.doi.org/10.21236/ada575846.
Texto completoReise, Michael. TGF-beta Type I Receptor Kinase Inhibitors - A Novel Treatment for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, junio de 2003. http://dx.doi.org/10.21236/ada416442.
Texto completoRausch, Matthew. Enhancement of Dendritic Cell-Based Immunotherapy Using a Small Molecule TGF-beta Receptor Type I Kinase Inhibitor. Fort Belvoir, VA: Defense Technical Information Center, junio de 2008. http://dx.doi.org/10.21236/ada487435.
Texto completoPlymate, Stephen R. Therapy of Prostate Cancer Using a Human Antibody Targeting the Type 1 Insulin-Like Growth Factor Receptor (IGF-IR). Fort Belvoir, VA: Defense Technical Information Center, septiembre de 2009. http://dx.doi.org/10.21236/ada524529.
Texto completoThomas, Tania, S. Shappell, S. Kasper, R. A. Serra y H. L. Moses. The Development and Characterization of a Transgenic Mouse Model Over-Expressing a Truncated TGF(Beta) Type II Receptor in the Prostate. Fort Belvoir, VA: Defense Technical Information Center, julio de 2000. http://dx.doi.org/10.21236/ada390670.
Texto completoZhuo, Chuanjun, Hongjun Tian, Lina Wang, Xiangyang Gao, Li Ding y Ming Liu. Comparative safety of glucagon like peptide‑1 receptor agonists in patients with type 2 diabetes: a network meta-analysis of cardiovascular outcome trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, agosto de 2020. http://dx.doi.org/10.37766/inplasy2020.8.0122.
Texto completoDeo, Salil, David McAllister, Naveed Sattar y Jill Pell. The time-varying cardiovascular benefits of glucagon like peptide-1 agonist (GLP-RA)therapy in patients with type 2 diabetes mellitus: A meta-analysis of multinational randomized trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, julio de 2021. http://dx.doi.org/10.37766/inplasy2021.7.0097.
Texto completo